{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-211935","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.071042+00:00","generated_at":"2026-05-14T22:00:44.446014+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement","bullets":["Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.","Cash of $117.2M as of March 31; April private placement raised $30M, extending runway into Q1 2028.","Phase 2b ADAPTIVE trial in AD advancing under amended protocol; topline data anticipated Q4 2027.","Plan to initiate Phase 2 in alopecia areata in 2026; initial data expected 2028, based on proof-of-concept."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-211935","json":"https://secwatch.observer/filing/0001193125-26-211935.json","markdown":"https://secwatch.observer/filing/0001193125-26-211935.md","text":"https://secwatch.observer/filing/0001193125-26-211935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/0001193125-26-211935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/d151394d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:00:44.446014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}